a study on Diabetes Type 1
The primary purpose of this study is to determine if golimumab can preserve beta-cell function in children and young adults with newly diagnosed Type 1 Diabetes (T1D).
SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes
Diabetes Mellitus, Type 1 Antibodies, Monoclonal
Open to people ages 6–21
Has a clinically active infection with Epstein-Barr virus (EBV) or an EBV viral load
=10,000 copies per 10^6 peripheral blood mononuclear cell (PBMCs) obtained at study screening. Has a clinically active infection with cytomegalovirus (CMV) or a CMV viral load>= 10,000 copies per milliliter (mL) whole blood obtained at study screening
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT02846545.
© The Regents of the University of California